1. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis
- Author
-
K Kotaniemi, Kristiina Aalto, Pekka Lahdenne, Pirjo Tynjälä, Katariina Latva, Visa Honkanen, and P Lindahl
- Subjects
Male ,musculoskeletal diseases ,medicine.medical_specialty ,Adolescent ,Injections, Subcutaneous ,Eye disease ,Arthritis ,Antibodies, Monoclonal, Humanized ,Risk Assessment ,Severity of Illness Index ,Drug Administration Schedule ,Statistics, Nonparametric ,Cohort Studies ,Rheumatology ,Internal medicine ,Adalimumab ,Humans ,Medicine ,Juvenile ,Pharmacology (medical) ,Child ,skin and connective tissue diseases ,Adverse effect ,Probability ,Retrospective Studies ,Dose-Response Relationship, Drug ,business.industry ,Antibodies, Monoclonal ,Retrospective cohort study ,medicine.disease ,Uveitis, Anterior ,Arthritis, Juvenile ,humanities ,Surgery ,Treatment Outcome ,Chronic Disease ,Female ,business ,Juvenile rheumatoid arthritis ,Uveitis ,Follow-Up Studies ,medicine.drug - Abstract
Objective. To evaluate the efficacy of adalimumab in juvenile idiopathic arthritis (JIA)-associated uveitis. Methods. Retrospective observational study of 20 patients with JIA and chronic uveitis on adalimumab treatment. The ocular inflammation and improvement was assessed according to the Standardization of Uveitis Nomenclature criteria. Results. At the initiation of adalimumab, the mean age of patients was 13.4 yrs and the mean duration of uveitis 8.7 yrs. Seventeen (85%) patients had polyarticular JIA and 19 (95%) had previously been on anti-TNF treatment. The mean duration of adalimumab therapy was 18.7 months. Of the 20 patients, 7 (35%) showed improved activity, 1 (5%) worsening activity and in 12 (60%) no change was observed in the activity of uveitis. Those with improved activity were younger and had shorter disease duration. The mean number of flares/yr decreased from 1.9 to 1.4 during adalimumab treatment. Serious adverse events or side-effects were not observed. Seven patients discontinued adalimumab during the follow-up: six because of inefficacy and one because of inactive uveitis. Conclusion. Adalimumab is a potential treatment option in JIA-associated uveitis, even in patients non-responsive to previous other anti-TNF therapy.
- Published
- 2007